The University of Chicago Header Logo

Connection

Mary Eileen Dolan to Guanine

This is a "connection" page, showing publications Mary Eileen Dolan has written about Guanine.
Connection Strength

8.172
  1. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet. 2012 Apr 01; 21(7):1470-80.
    View in: PubMed
    Score: 0.386
  2. Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol. 2009 Jun; 64(1):133-42.
    View in: PubMed
    Score: 0.312
  3. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther. 2008 Nov; 327(2):442-52.
    View in: PubMed
    Score: 0.306
  4. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 01; 25(4):399-404.
    View in: PubMed
    Score: 0.276
  5. Role of GADD34 in modulation of cisplatin cytotoxicity. Biochem Pharmacol. 2006 Jan 12; 71(3):239-47.
    View in: PubMed
    Score: 0.254
  6. Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities. J Pharmacol Exp Ther. 2005 Dec; 315(3):1247-55.
    View in: PubMed
    Score: 0.250
  7. Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):333-342.
    View in: PubMed
    Score: 0.234
  8. Effect of cell cycle inhibition on Cisplatin-induced cytotoxicity. J Pharmacol Exp Ther. 2005 Jan; 312(1):206-13.
    View in: PubMed
    Score: 0.232
  9. Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. Cancer Chemother Pharmacol. 2003 Oct; 52(4):291-302.
    View in: PubMed
    Score: 0.215
  10. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther. 2003 Jul; 2(7):633-40.
    View in: PubMed
    Score: 0.215
  11. O6-benzylguanine-mediated enhancement of chemotherapy. Mol Cancer Ther. 2002 Sep; 1(11):943-8.
    View in: PubMed
    Score: 0.203
  12. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.202
  13. Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec; 7(12):4239-44.
    View in: PubMed
    Score: 0.193
  14. Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells. Mol Cancer Ther. 2001 Nov; 1(1):21-8.
    View in: PubMed
    Score: 0.192
  15. Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism. Biochem Pharmacol. 2001 Mar 15; 61(6):721-6.
    View in: PubMed
    Score: 0.183
  16. Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice. Cancer Chemother Pharmacol. 2001; 47(1):63-9.
    View in: PubMed
    Score: 0.181
  17. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2000 Oct 15; 18(20):3522-8.
    View in: PubMed
    Score: 0.178
  18. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res. 2000 Oct 01; 60(19):5464-9.
    View in: PubMed
    Score: 0.178
  19. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates. Clin Cancer Res. 2000 Sep; 6(9):3662-9.
    View in: PubMed
    Score: 0.177
  20. Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. Cancer Chemother Pharmacol. 2000; 46(2):150-5.
    View in: PubMed
    Score: 0.169
  21. Determination of 8-oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl. 1999 Aug 20; 731(2):241-9.
    View in: PubMed
    Score: 0.164
  22. O6-alkylguanine-DNA alkyltransferase inactivation by ester prodrugs of O6-benzylguanine derivatives and their rate of hydrolysis by cellular esterases. Biochem Pharmacol. 1998 May 15; 55(10):1701-9.
    View in: PubMed
    Score: 0.151
  23. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
    View in: PubMed
    Score: 0.150
  24. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997 Jun; 3(6):837-47.
    View in: PubMed
    Score: 0.141
  25. Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos. 1995 Dec; 23(12):1394-9.
    View in: PubMed
    Score: 0.127
  26. Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 1995 Oct 26; 50(9):1385-9.
    View in: PubMed
    Score: 0.126
  27. Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Cancer Res. 1994 Oct 01; 54(19):5123-30.
    View in: PubMed
    Score: 0.117
  28. Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemother Pharmacol. 1994; 35(2):121-6.
    View in: PubMed
    Score: 0.111
  29. Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine. Biochemistry. 1993 Nov 16; 32(45):11998-2006.
    View in: PubMed
    Score: 0.110
  30. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol. 1993 Jul 20; 46(2):285-90.
    View in: PubMed
    Score: 0.108
  31. Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol. 1993; 32(3):221-5.
    View in: PubMed
    Score: 0.104
  32. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res. 1992 Mar 01; 52(5):1171-5.
    View in: PubMed
    Score: 0.098
  33. Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine. Carcinogenesis. 1991 Dec; 12(12):2305-9.
    View in: PubMed
    Score: 0.096
  34. Use of antibodies to human O6-alkylguanine-DNA alkyltransferase to study the content of this protein in cells treated with O6-benzylguanine or N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1991 Sep; 12(9):1679-83.
    View in: PubMed
    Score: 0.095
  35. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet Genomics. 2011 Aug; 21(8):476-88.
    View in: PubMed
    Score: 0.094
  36. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res. 1991 Jul 01; 51(13):3367-72.
    View in: PubMed
    Score: 0.094
  37. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A. 1990 Jul; 87(14):5368-72.
    View in: PubMed
    Score: 0.087
  38. Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 1990; 2(11):371-7.
    View in: PubMed
    Score: 0.084
  39. Expression of mammalian O6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents. Carcinogenesis. 1989 Sep; 10(9):1613-9.
    View in: PubMed
    Score: 0.082
  40. The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2. Biochem Pharmacol. 2009 May 15; 77(10):1586-92.
    View in: PubMed
    Score: 0.080
  41. Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine. Cancer Chemother Pharmacol. 1989; 25(2):103-8.
    View in: PubMed
    Score: 0.079
  42. Sequence specificity of guanine alkylation and repair. Carcinogenesis. 1988 Nov; 9(11):2139-43.
    View in: PubMed
    Score: 0.078
  43. Effect of O6-methylguanine on DNA interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl(methylsulfonyl)methanesulfonate. Cancer Res. 1988 Jul 01; 48(13):3603-6.
    View in: PubMed
    Score: 0.076
  44. Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res. 2007 Jul 15; 67(14):6889-98.
    View in: PubMed
    Score: 0.071
  45. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis. 2007 May; 28(5):1111-6.
    View in: PubMed
    Score: 0.068
  46. Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev. 2006 Jun; 32(4):261-76.
    View in: PubMed
    Score: 0.066
  47. Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines. Cancer Res. 1985 Dec; 45(12 Pt 1):6413-7.
    View in: PubMed
    Score: 0.064
  48. Exposure of HeLa cells to 0(6)-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents. Biochem Biophys Res Commun. 1985 Oct 15; 132(1):178-85.
    View in: PubMed
    Score: 0.063
  49. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther. 2004 Sep; 3(9):1127-35.
    View in: PubMed
    Score: 0.058
  50. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83.
    View in: PubMed
    Score: 0.050
  51. Modified guanines representing O(6)-alkylation by the cyclophosphamide metabolites acrolein and chloroacetaldehyde: synthesis, stability, and ab initio studies. Chem Res Toxicol. 2002 Mar; 15(3):380-7.
    View in: PubMed
    Score: 0.049
  52. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res. 2000 Nov 15; 60(22):6307-10.
    View in: PubMed
    Score: 0.045
  53. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
    View in: PubMed
    Score: 0.044
  54. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. Cancer Chemother Pharmacol. 2000; 45(6):437-40.
    View in: PubMed
    Score: 0.042
  55. Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
    View in: PubMed
    Score: 0.039
  56. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol. 1998 Nov; 16(11):3570-5.
    View in: PubMed
    Score: 0.039
  57. Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1997; 39(4):307-16.
    View in: PubMed
    Score: 0.034
  58. Increased killing of prostate, breast, colon, and lung tumor cells by the combination of inactivators of O6-alkylguanine-DNA alkyltransferase and N,N'-bis(2-chloroethyl)-N-nitrosourea. Biochem Pharmacol. 1995 Oct 12; 50(8):1141-8.
    View in: PubMed
    Score: 0.031
  59. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995 Jul 01; 55(13):2853-7.
    View in: PubMed
    Score: 0.031
  60. 8-Substituted O6-benzylguanine, substituted 6(4)-(benzyloxy)pyrimidine, and related derivatives as inactivators of human O6-alkylguanine-DNA alkyltransferase. J Med Chem. 1995 Jan 20; 38(2):359-65.
    View in: PubMed
    Score: 0.030
  61. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res. 1994 Aug 15; 54(16):4371-5.
    View in: PubMed
    Score: 0.029
  62. Substituted O6-benzylguanine derivatives and their inactivation of human O6-alkylguanine-DNA alkyltransferase. J Med Chem. 1994 Feb 04; 37(3):342-7.
    View in: PubMed
    Score: 0.028
  63. Prolonged depletion of O6-methylguanine DNA methyltransferase activity following exposure to O6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res. 1993 Sep 15; 53(18):4281-6.
    View in: PubMed
    Score: 0.027
  64. Supplemental dietary calcium fails to alter the acute effects of 1,2-dimethylhydrazine on O6-methylguanine, O6-alkylguanine-DNA alkyltransferase and cellular proliferation in the rat colon. Carcinogenesis. 1993 Jun; 14(6):1175-9.
    View in: PubMed
    Score: 0.027
  65. The role of O6-alkylguanine-DNA alkyltransferase in protecting Rat4 cells against the mutagenic effects of O6-substituted guanine residues incorporated in codon 12 of the H-ras gene. Carcinogenesis. 1993 Apr; 14(4):593-8.
    View in: PubMed
    Score: 0.026
  66. The effects of O6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol. 1993; 32(6):477-81.
    View in: PubMed
    Score: 0.026
  67. Cell specific differences in O6-methylguanine-DNA methyltransferase activity and removal of O6-methylguanine in rat pulmonary cells. Carcinogenesis. 1988 Nov; 9(11):2053-8.
    View in: PubMed
    Score: 0.019
  68. Use of oligodeoxynucleotides containing O6-alkylguanine for the assay of O6-alkylguanine-DNA-alkyltransferase activity. Cancer Res. 1988 Mar 01; 48(5):1184-8.
    View in: PubMed
    Score: 0.019
  69. Investigation of the specificity of O6-alkylguanine-DNA-alkyltransferase. Chem Biol Interact. 1988; 65(3):275-81.
    View in: PubMed
    Score: 0.018
  70. Specificity of O6-alkylguanine-DNA alkyltransferase. IARC Sci Publ. 1987; (84):30-4.
    View in: PubMed
    Score: 0.017
  71. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother Pharmacol. 2006 Nov; 58(5):634-9.
    View in: PubMed
    Score: 0.016
  72. Studies of the repair of O6-alkylguanine and O4-alkylthymine in DNA by alkyltransferases from mammalian cells and bacteria. Environ Health Perspect. 1985 Oct; 62:109-14.
    View in: PubMed
    Score: 0.016
  73. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 01; 23(28):7178-87.
    View in: PubMed
    Score: 0.016
  74. Repair of O6-propylguanine and O6-butylguanine in DNA by O6-alkylguanine-DNA alkyltransferases from rat liver and E. coli. Carcinogenesis. 1985 Jul; 6(7):1027-31.
    View in: PubMed
    Score: 0.015
  75. Comparison of repair of methylated pyrimidines in poly(dT) by extracts from rat liver and Escherichia coli. Biochem Biophys Res Commun. 1984 Aug 30; 123(1):324-30.
    View in: PubMed
    Score: 0.015
  76. Inhibition of O(6)-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats. Carcinogenesis. 1999 Dec; 20(12):2355-60.
    View in: PubMed
    Score: 0.010
  77. Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol. 1996; 37(6):547-55.
    View in: PubMed
    Score: 0.008
  78. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo. Biochem Pharmacol. 1994 Nov 29; 48(11):2127-34.
    View in: PubMed
    Score: 0.007
  79. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol. 1993; 32(6):471-6.
    View in: PubMed
    Score: 0.006
  80. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst. 1992 Dec 16; 84(24):1926-31.
    View in: PubMed
    Score: 0.006
  81. Effect of O6-alkylguanine-DNA alkyltransferase on the frequency and spectrum of mutations induced by N-methyl-N'-nitro-N-nitrosoguanidine in the HPRT gene of diploid human fibroblasts. Mutat Res. 1991 Sep-Oct; 250(1-2):397-409.
    View in: PubMed
    Score: 0.006
  82. Depletion of O6-methylguanine-DNA-methyltransferase in human fibroblasts increases the mutagenic response to N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1985 Dec; 6(12):1823-6.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.